19–20 June 2026 the company "RAYMED GROUP" took part in the TREC 2026 — conference, a key event for specialists in the field of interventional cardioangiology. The conference was held in Moscow, at the Hyatt Regency Moscow Petrovsky Park hotel, and brought together leading experts from the medical community, manufacturers of equipment and medical devices.
The importance of participation in the conference
For "RAYMED GROUP" participation in TREC 2026 was a significant event: it made it possible to discuss the most important issues of the development of domestic interventional medicine, the achievement of technological sovereignty and the prospects for Russian production of high-tech medical devices.
Key events involving the company
-
Establishment of the RAYMED GROUP Award— CELT. Founder and CEO of RAYMED GROUP Rajeev Kumar announced the creation of an award for young interventional cardiac angiologists. The purpose of the award — is to support beginning specialists, stimulate scientific research, introduce innovations into practice and form a new generation of industry leaders.
-
Speech at the symposium. Rajeev Kumar took part in the symposium “Domestic manufacturers of instruments for interventional cardioangiology: current status and development prospects.” In his report, he presented a strategy for the development of domestic production of high-tech products for interventional cardiology and spoke about the company's current product line.
Product line presented at the conference
The event participants were shown five key products of RAYMED GROUP:
-
coronary balloon catheter NC RAMA;
-
RAMA coronary balloon catheter;
-
drug-eluting coronary stent sirolimus PUTNIY;
-
cobalt-chromium coronary stent with drug-eluting everolimus NASH+;
-
R‑STANT coronary stent with sirolimus eluting.
Strategic priorities of the company
The report paid special attention to the following areas:
-
development of domestic production in the field of interventional cardioangiology;
-
introduction of international technologies;
-
creating a full cycle of medical ecosystem — from development and production to clinical use and patient support.
Today "RAYMED GROUP" consistently implements a strategy to increase Russian production of high-tech products for interventional cardiology, while simultaneously developing the clinical area and introducing modern standards of medical care.
Participation in TREC 2026 provided the company with a valuable opportunity to exchange experience with the professional community and jointly discuss the future of Russian interventional cardioangiology.
